News
The European Medicines Agency has recommended marketing approval for Alyftrek for cystic fibrosis and Attrogy for a form of hereditary amyloidosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback